Governor Hobbs’ veto of Arizona’s psilocybin therapy bill halts a regulated, evidence-based program despite growing clinical support and successful models in other states.
Arizona’s recent bid to legalize supervised psilocybin therapy centers has stirred intense debate, attracting both cautious skeptics and passionate advocates. While critics raise flags about the pace of progress, supporters point to a deep and growing record of therapeutic success.
From centuries of indigenous ceremonial use to a modern resurgence in neuroscience and mental health treatment, psilocybin has consistently shown promise as a transformative therapeutic tool. Scientifically, the compound’s agonism at serotonin 2A receptors stimulates neuroplasticity, opening the brain to long-term rewiring that often translates to rapid and lasting symptom relief.
Clinical evidence from institutions like Johns Hopkins and Imperial College London reinforces this biological mechanism with data. Across multiple trials, patients suffering from treatment-resistant depression and PTSD have reported meaningful, durable outcomes from as few as one or two guided psilocybin sessions.
These results challenge the outdated notion that psilocybin remains in unproven territory. Despite the growing scientific consensus, Arizona Gov. Katie Hobbs vetoed HB 1570 in mid-2024, arguing the bill lacked sufficient data and “appropriate guardrails.”
The decision halted what would have been a carefully structured pilot program. Yet the very structure of HB 1570 contradicts the concerns raised.
The bill outlined clear facility requirements, including clinical-grade environments with onsite emergency protocols and mandatory digital tracking of adverse events. Facilitators would have been required to complete at least 100 hours of specialized training in psychedelic-assisted therapy, undergo background checks, and maintain continuing education.
Integration therapy before and after each session was codified into the bill’s framework—a component critical to the successful outcomes observed in landmark trials.
These aren’t suggestions. They’re structured mandates. And they echo standards already deployed in Oregon, where more than 3,500 state-sanctioned psilocybin therapy sessions have occurred without major incident.
What the Arizona framework proposed was not experimentation. It was a controlled rollout. Under HB 1570, oversight would fall to a state-appointed advisory board comprising clinicians, researchers, veterans, and first responders.
That board would have been tasked with publishing annual public reports, analyzing session data, safety outcomes, equity metrics, and financial audits. This governance model—far from ad hoc or impulsive—parallels other state approaches that have yielded measurable public benefit.
Much of the veto rationale hinges on the assertion that psilocybin therapy lacks adequate proof. But decades of research refute that notion. Studies have consistently demonstrated high efficacy and safety when psilocybin is administered under controlled conditions.
One randomized trial comparing psilocybin to escitalopram (a common SSRI) found not only comparable outcomes, but quicker and more profound relief from depressive symptoms. Another study noted that 71% of participants experienced a clinically significant improvement one month after treatment.
Long-term safety data reveal no evidence of dependency, abuse potential, or lasting physiological harm. When side effects do occur, they tend to be transient and mild, such as temporary anxiety. And in nearly every study, adverse reactions have been mitigated through protocols that already mirror those baked into Arizona’s proposed law.
Patients, especially veterans and first responders, often describe the experience as transformational—not just for its effects on mood and mental clarity, but for its restoration of purpose, sleep, and social connection.
Arizona would not have been the first to test this ground. Oregon, California, Colorado, and Vermont each offer instructive examples. Oregon’s Measure 109 implemented a regulated psilocybin therapy program in 2023. Its real-time dashboard tracks thousands of sessions, patient demographics, and incident reports.
California, after vetoing SB 58 for lack of structure, pivoted to SB 1012—a nearly identical bill to Arizona’s HB 1570 that includes clinical screening, facilitator licensing, integration therapy, and dose limitations. Colorado, meanwhile, passed legislation requiring anonymized outcome data collection from all healing centers.
Vermont, more cautiously, has created an advisory panel tasked with reviewing international evidence and producing policy recommendations.
Financially, the program would not have burdened the state. Arizona already allocates $5 million annually to psilocybin research, a fund protected even under the governor’s veto. HB 1570 requested $400,000 to support regulatory staff and data systems—a modest sum that could have been offset by licensing and session fees.
Oregon’s model is self-sustaining through its fee structure, and early analyses suggest long-term cost savings from reduced psychiatric medication use, fewer hospitalizations, and greater occupational stability.
If fiscal scrutiny still lingers, it should be measured against the social cost of inaction. Untreated PTSD, depression, and anxiety extract a far greater toll—not just in dollars, but in lives diminished or lost. It’s within that context that psilocybin therapy offers not just hope, but an evidence-backed path to healing.
Veterans in particular have led the call for change, reporting up to 60% reductions in symptom severity after structured sessions. First responders echo similar outcomes, crediting guided psilocybin sessions with delivering the kind of relief years of pharmaceutical intervention could not.
These are not rogue actors experimenting in basements. These are people following protocols developed in controlled trials and refined by some of the top research institutions in the world. Their stories make a compelling case that psilocybin therapy, when delivered responsibly, belongs within the scope of public health solutions, not locked away behind political apprehension.
Arizona now has an opportunity to revisit HB 1570 with a few refinements and a more robust public outreach campaign. A phased pilot program could launch in limited regions with built-in sunset clauses and outcome evaluations.
Transparency should be a priority: real-time public dashboards, independent audits, and measurable health indicators will build the public trust needed to move forward. Equity should be a pillar of that design—ensuring access to rural communities and underserved groups, and providing scholarships for facilitators from marginalized backgrounds.
In the end, the question isn’t whether psilocybin therapy is a panacea. It’s whether Arizona is willing to acknowledge the evidence in front of it, to proceed with rigor and compassion, and to give suffering individuals a chance at relief rooted not in ideology, but in data.
What the veto left behind wasn’t just a missed opportunity. It was a moment deferred—one that can and should return, this time backed by clarity, accountability, and the courage to lead with science.
***
GreenPharms is more than just a dispensary. We are a family-owned and operated company that cultivates, processes, and sells high-quality cannabis products in Arizona. Whether you are looking for medical or recreational marijuana, we have something for everyone. From flower, edibles, concentrates, and topicals, to accessories, apparel, and education, we offer a wide range of marijuana strains, products and services to suit your needs and preferences. Our friendly and knowledgeable staff are always ready to assist you and answer any questions you may have. Visit our dispensaries in Mesa and Flagstaff, or shop online and get your order delivered to your door. At GreenPharms, we are cultivating a different kind of care.
Follow us on social media
